Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
30 participants
INTERVENTIONAL
2022-11-28
2027-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objectives:
1. Investigate the feasibility, safety, and acceptability of psilocybin for OCD.
2. Investigate the effect of psilocybin on OCD symptoms and concomitant depression and anxiety symptoms.
3. Investigate the effect of psilocybin on quality of life.
Secondary objectives:
1. Investigate the effect of psilocybin on metacognition of episodic memory and decision-making.
2. Investigate the effect of psilocybin on model-based learning.
3. Investigate the effect of psilocybin on the ERN.
4. Investigate the effect of psilocybin on affect and social connection.
5. Investigate the effect of psilocybin on movement and communications.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immediate Psilocybin
This arm will receive two sessions of psilocybin first (20mg in first session and then, if well tolerated, 30mg).
Psilocybin
Psilocybin administration under supportive conditions
Delayed Psilocybin
Waitlist control. This arm will receive psilocybin after the waiting period is over (20mg in first session and then, if well tolerated, 30mg).
Psilocybin
Psilocybin administration under supportive conditions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Psilocybin
Psilocybin administration under supportive conditions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently meet criteria for a DSM-5 diagnosis of OCD and report a history of OCD for at least 1 year prior to screening
* Have a Y-BOCS score of 18 or more
* Have at least one prior attempt at treatment, either ERP or pharmacotherapy
* No antidepressant medications for approximately five half-lives prior to acceptance in treatment phase of study
* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control must agree to practice an effective means of birth control throughout the duration of the study
* Be judged by study team clinicians to be at low risk for suicidality
* Concurrent psychotherapy is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening and is expected to remain stable during participation in the study
* Be otherwise medically stable as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests (CBC, CMP, urine beta-HCG, urine toxicology screen)
* Agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of drug session days. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on session days
* Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of each drug administration. The exceptions are caffeine and nicotine
* Agree not to take any PRN medications on the mornings of drug sessions
* Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration
* Agree that for one week before each drug session, he/she will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the study investigators. Exceptions will be evaluated by the study investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
* Have limited lifetime use of hallucinogens (the following criteria are preferred: no use in the past 5 years; total hallucinogen use less than 10 times)
Exclusion Criteria
* Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing
* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control
* Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled hypertension, a clinically significant ECG abnormality (e.g., atrial fibrillation), prolonged QTc interval (i.e., QTc \> 450 msec), heart valve, or transient ischemic attack (TIA) in the past year
* Epilepsy with history of seizures
* Type 1 diabetes
* BMI \< 18
* Currently taking on a regular (e.g., daily) basis any psychoactive prescription medication or any medications having a primary centrally-acting serotonergic effect, or MAOIs. For individuals who have intermittent or PRN use of such medications, psilocybin sessions will not be conducted until approximately five half-lives of the agent have elapsed after the last dose.
* Current (severe) migraine or other recurring severe headaches
* Current or past history of meeting DSM-5 criteria for schizophrenia spectrum or other psychotic disorders (except substance-/medication-induced or due to another medical condition), or bipolar I disorder
* Current or history within one year of meeting DSM-5 criteria for a moderate or severe alcohol, or other drug use disorder (excluding tobacco and caffeine)
* Nicotine dependence that would be incompatible with an individual to be nicotine free for 8-10 hours on a psilocybin session day
* Have a first degree relative with schizophrenia or other psychotic disorders (except substance/medication-induced or due to another medical condition), or bipolar I disorder
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
Usona Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David B Yaden, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
David B Yaden, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov;46(11):1006-11. doi: 10.1001/archpsyc.1989.01810110048007.
Spilberger, C. (1983). Manual for the state-trait anxiety inventory: STAI (Form Y). Palo Alto.
Beck, A.T., Steer, R.A. and Brown, G.K. (1996) Beck Depression Inventory-II. San Antonio, 78, 490-498.
Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.
Doss MK, Weafer J, Gallo DA, de Wit H. Delta9-Tetrahydrocannabinol at Retrieval Drives False Recollection of Neutral and Emotional Memories. Biol Psychiatry. 2018 Nov 15;84(10):743-750. doi: 10.1016/j.biopsych.2018.04.020. Epub 2018 May 9.
Doss MK, Weafer J, Gallo DA, de Wit H. MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections. Neuropsychopharmacology. 2018 Mar;43(4):791-800. doi: 10.1038/npp.2017.171. Epub 2017 Aug 21.
Banca P, Vestergaard MD, Rankov V, Baek K, Mitchell S, Lapa T, Castelo-Branco M, Voon V. Evidence accumulation in obsessive-compulsive disorder: the role of uncertainty and monetary reward on perceptual decision-making thresholds. Neuropsychopharmacology. 2015 Mar 13;40(5):1192-202. doi: 10.1038/npp.2014.303.
Marton T, Samuels J, Nestadt P, Krasnow J, Wang Y, Shuler M, Kamath V, Chib VS, Bakker A, Nestadt G. Validating a dimension of doubt in decision-making: A proposed endophenotype for obsessive-compulsive disorder. PLoS One. 2019 Jun 13;14(6):e0218182. doi: 10.1371/journal.pone.0218182. eCollection 2019.
Daw ND, Gershman SJ, Seymour B, Dayan P, Dolan RJ. Model-based influences on humans' choices and striatal prediction errors. Neuron. 2011 Mar 24;69(6):1204-15. doi: 10.1016/j.neuron.2011.02.027.
Gillan CM, Kalanthroff E, Evans M, Weingarden HM, Jacoby RJ, Gershkovich M, Snorrason I, Campeas R, Cervoni C, Crimarco NC, Sokol Y, Garnaat SL, McLaughlin NCR, Phelps EA, Pinto A, Boisseau CL, Wilhelm S, Daw ND, Simpson HB. Comparison of the Association Between Goal-Directed Planning and Self-reported Compulsivity vs Obsessive-Compulsive Disorder Diagnosis. JAMA Psychiatry. 2020 Jan 1;77(1):77-85. doi: 10.1001/jamapsychiatry.2019.2998.
Grundler TO, Cavanagh JF, Figueroa CM, Frank MJ, Allen JJ. Task-related dissociation in ERN amplitude as a function of obsessive-compulsive symptoms. Neuropsychologia. 2009 Jul;47(8-9):1978-87. doi: 10.1016/j.neuropsychologia.2009.03.010. Epub 2009 Mar 17.
Riesel A, Goldhahn S, Kathmann N. Hyperactive performance monitoring as a transdiagnostic marker: Results from health anxiety in comparison to obsessive-compulsive disorder. Neuropsychologia. 2017 Feb;96:1-8. doi: 10.1016/j.neuropsychologia.2016.12.029. Epub 2016 Dec 29.
John, O. P., Naumann, L. P., & Soto, C. J. (2008). Paradigm shift to the integrative Big Five trait taxonomy: History, measurement, and conceptual issues. Handbook of Personality: Theory and Research, 3rd Ed., 114.
Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. doi: 10.1097/00005650-199603000-00003.
Guy, W. (1976). ECDEU assessment manual for psychopharmacology-revised (DHEW publ no ADM 76-338). rockville, MD, US department of health, education, and welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1076, 534-537.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00284207
Identifier Type: -
Identifier Source: org_study_id